A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects
NCT ID: NCT03350347
Last Updated: 2021-01-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
164 participants
INTERVENTIONAL
2017-12-13
2019-11-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects
NCT03350321
Maintenance Treatment of Renal Anemia in Dialysis Subjects
NCT03543657
A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects
NCT03351166
A Study to Learn More About the Long-term Safety and Effectiveness of Molidustat as a Treatment for Japanese Men and Women With Renal Anemia
NCT04899661
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
NCT01975818
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Molidustat (BAY85-3934)
Molidustat group
Molidustat (BAY85-3934)
Starting dose of 25 mg or 50 mg molidustat once daily (OD) will be titrated based on the subject's Hb response
Darbepoetin alfa
Darbepoetin alfa group
Darbepoetin alfa
Starting dose and frequency of darbepoetin alfa are based on previous ESA. The dose will be titrated based on the subject's Hb response
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Molidustat (BAY85-3934)
Starting dose of 25 mg or 50 mg molidustat once daily (OD) will be titrated based on the subject's Hb response
Darbepoetin alfa
Starting dose and frequency of darbepoetin alfa are based on previous ESA. The dose will be titrated based on the subject's Hb response
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have used the same ESA for 8 weeks prior to screening
* Treated with darbepoetin alfa with bi-weekly or monthly dose, epoetin beta pegol with monthly, OR epoetin alfa/beta weekly or bi-weekly, and having had no more than one dose change within 8 weeks prior to randomization
* Body weight \> 40 and ≤ 160 kg at screening
* Male or female subject ≥ 20 years of age at screening
* Not on dialysis and not expected to start dialysis during the study period
* Mean screening Hb level ≥ 10.0 and \< 13.0 g/dL (mean of all central laboratory Hb levels \[at least 2 measurements must be taken ≥ 2 days apart\] during the 8-week screening period, AND all Hb level must be measured by the central laboratory, AND the difference between the lowest level and highest level is \< 1.2 g/dL), with the last screening Hb level measurement within 14 days prior to randomization
* Ferritin ≥ 100 ng/mL or Transferrin saturation ≥ 20%
Exclusion Criteria
* History of cardio- (cerebro-) vascular events (e.g., unstable angina, myocardial infarction, stroke, pulmonary thromboembolism, and acute limb ischemia) within 6 months prior to randomization
* Sustained and poorly controlled arterial hypertension (defined as systolic BP (blood pressure)≥ 180mmHg or diastolic BP ≥ 110mmHg) or hypotension (defined as systolic BP \< 90mmHg) at randomization
* Proliferative choroidal or retinal disease, such as neovascular age-related macular degeneration or proliferative diabetic retinopathy requiring invasive treatment (e.g., intraocular injections or laser photocoagulation)
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kainan Hospital
Yatomi, Aichi-ken, Japan
Seikeikai New Tokyo Heart Clinic
Matsudo, Chiba, Japan
Ehime Prefectural Central Hospital
Matsuyama, Ehime, Japan
Saiseikai Matsuyama Hospital
Matsuyama, Ehime, Japan
Iizuka Hospital
Iizuka, Fukuoka, Japan
Kokura Memorial Hospital
Kitakyushu, Fukuoka, Japan
Steel Memorial Yawata Hospital
Kitakyushu, Fukuoka, Japan
National Fukuoka-Higashi Medical Center
Koga, Fukuoka, Japan
Kurume University Hospital
Kurume, Fukuoka, Japan
St.Mary's Hospital
Kurume, Fukuoka, Japan
Matsunami Health Promotion Clinic
Hashima-gun, Gifu, Japan
Mazda Hospital of Mazda Motor Corporation
Aki-gun, Hiroshima, Japan
Nippon Kokan Fukuyama Hospital
Fukuyama, Hiroshima, Japan
Higashihiroshima Medical Center
Higashihiroshima, Hiroshima, Japan
Teine Keijinkai Clinic
Sapporo, Hokkaido, Japan
Kobe City Medical Center General Hospital
Kobe, Hyōgo, Japan
National Hospital Organization Kobe Medical Center
Kobe, Hyōgo, Japan
Mito Kyodo General Hospital
Mito, Ibaraki, Japan
Public Central Hospital of Matto Ishikawa
Hakusan, Ishikawa-ken, Japan
KenAiKai medical corporation Akiyama clinic
Takamatsu, Kagawa-ken, Japan
Ikeda Hospital
Kanoya, Kagoshima-ken, Japan
Fujisawa City Hospital
Fujisawa, Kanagawa, Japan
Koukan Clinic
Kawasaki, Kanagawa, Japan
Showa University Fujigaoka Hospital
Yokohama, Kanagawa, Japan
Yokosuka Kyosai Hospital
Yokosuka, Kanagawa, Japan
Arao Municipal Hospital
Arao, Kumamoto, Japan
JCHO Yokkaichi Hazu Medical Center
Yokkaichi, Mie-ken, Japan
Japanese Red Cross Ishinomaki Hospital
Ishinomaki, Miyagi, Japan
Asama Nanroku Komoro Medical Center
Komoro, Nagano, Japan
Niigata Prefectural Shibata Hospital
Shibata, Niigata, Japan
R.I.A.C Naha City Hospital
Naha, Okinawa, Japan
Osaka Pref. Saiseikai Tondabayashi Hospital
Tondabayashi, Osaka, Japan
Kitasato University Medical Center
Kitamoto, Saitama, Japan
Iwata City Hospital
Iwata, Shizuoka, Japan
Toshima Hospital
Itabashi-ku, Tokyo, Japan
Nihon University Itabashi Hospital
Itabashi-ku, Tokyo, Japan
Showa University Koto Toyosu Hospital
Koto-ku, Tokyo, Japan
National Hospital Organization Tokyo Medical Center
Meguro-ku, Tokyo, Japan
University of Yamanashi Hospital
Chūō, Yamanashi, Japan
Fukui Prefectural Hospital
Fukui, , Japan
National Hospital Organization Kyushu Medical Center
Fukuoka, , Japan
Kyushu University Hospital
Fukuoka, , Japan
Fukuoka University Hospital
Fukuoka, , Japan
Asahi University Hospital
Gifu, , Japan
National Hospital Organization Kochi National Hospital
Kochi, , Japan
Miyazaki Prefectural Miyazaki Hospital
Miyazaki, , Japan
Nara Prefecture General Medical Center
Nara, , Japan
Kitano Hospital
Osaka, , Japan
Yodogawa Christian Hospital
Osaka, , Japan
National Hospital Organization Osaka National Hospital
Osaka, , Japan
Osaka Red Cross Hospital
Osaka, , Japan
Nippon Life Hospital
Osaka, , Japan
Chibune Clinic
Osaka, , Japan
Osaka General Medical Center
Osaka, , Japan
Social Corporation Keigakukai Minamiosaka Hospital
Osaka, , Japan
Japanese Red Cross Oita Hospital
Ōita, , Japan
Shizuoka Saiseikai General Hospital
Shizuoka, , Japan
Suruga Clinic
Shizuoka, , Japan
Wakayama Medical University Hospital
Wakayama, , Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Yamamoto H, Yamada T, Miyazaki K, Yamashita T, Kato T, Ohara K, Nakamura Y, Akizawa T. Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials. Clin Exp Nephrol. 2023 Aug;27(8):651-659. doi: 10.1007/s10157-023-02353-x. Epub 2023 Apr 24.
Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2.
Yamamoto H, Taguchi M, Matsuda Y, Iekushi K, Yamada T, Akizawa T. Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open. 2019 Jun 14;9(6):e026704. doi: 10.1136/bmjopen-2018-026704.
Related Links
Access external resources that provide additional context or updates about the study.
Click here to find results for studies related to Bayer products
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19350
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.